Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform.Under the multi-year collaboration agreement, Guardant and Pfizer aim to:Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies.Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor therapy response and (b) related blood-based epigenomic analyses.Also …Full story available on Benzinga.com
